Priapism

Priapism is a persistent penile erection that continues hours beyond, or is entirely unrelated to, sexual stimulation, restricted for the purposes of this chapter to erections lasting more than four hours; only the paired corpora cavernosa are affected, while the corpus spongiosum and glans remain uninvolved.^[1] There are two fundamentally different subtypes, and telling them apart is the single most important diagnostic step in every case:

A third pattern, recurrent (stuttering) ischemic priapism, describes a patient who experiences repeated ischemic episodes over time — with or without each individual episode meeting the four-hour duration criterion — separated by intervals of normal detumescence. It is especially common in sickle cell disease but also occurs idiopathically, and every episode that does meet ischemic criteria requires exactly the same emergency management as a first presentation.^[1]

Pathophysiology and the corporal-damage timeline

Ischemic priapism is fundamentally a venous outflow (compartment syndrome-like) problem: a failure of the normal detumescence mechanism traps blood in the corpora cavernosa, which then becomes progressively hypoxic, hypercarbic, and acidotic. This anoxic, acidotic environment directly impairs the smooth muscle's ability to respond even to pharmacologic (sympathomimetic) stimulation, which is why response rates to intracavernosal therapy fall the longer an episode has lasted.^[1] Histopathology from patients with prolonged, unresolved acute ischemic priapism corroborates the clinical urgency: the proportion of viable corporal smooth-muscle tissue on biopsy fell steadily with duration of the episode in more than one series, with fibrosis and necrosis first appearing as early as 12-24 hours and no viable tissue at all remaining by 36 hours in one cohort.^[1] Duration of priapism correlates directly and significantly with post-treatment erectile function: across pooled retrospective data, patients with acute ischemic priapism lasting under 48 hours retained meaningfully better post-operative erectile function scores than those whose episodes lasted longer, and more than half of patients with priapism lasting 24-48 hours were left with permanent erectile dysfunction.^[1]

Drug-induced priapism — a genuinely pharmacist-relevant etiology

Medications and recreational substances are a common and often overlooked cause of ischemic priapism, and recognizing them changes both acute management (do not assume idiopathic disease) and long-term counselling (stopping or switching the causative agent, where clinically appropriate, is part of secondary prevention). The documented classes are broad:

• Intracavernosal injection (ICI) therapy for erectile dysfunction — the single most direct, mechanistically obvious drug cause. Alprostadil, papaverine, and phentolamine are all vasoactive agents injected specifically to produce an erection, and any one of them, alone or in the combination regimens sometimes called "Trimix" or "Bimix," can produce an erection that fails to detumesce on its own.^[1] This is why every patient starting ICI therapy — whether self-administered at home or given as in-office teaching — must be explicitly counselled before their first injection that an erection lasting more than four hours is not a side effect to wait out, but a reason to seek care immediately (see Special Populations).^[1]
• PDE5 inhibitors (sildenafil, tadalafil, vardenafil) — an association that is genuinely real but easy for both patients and clinicians to misjudge. A 2023 disproportionality analysis of the World Health Organization pharmacovigilance database found significantly elevated reporting odds ratios for priapism across all three major oral PDE5 inhibitors (sildenafil 13.81, tadalafil 14.54, vardenafil 14.12), confirming a genuine safety signal even though absolute reported event counts remain low.^[2] Reported cases cluster heavily in men with an additional risk factor layered on top of the PDE5 inhibitor — sickle cell disease, spinal cord injury, concurrent ICI use, recreational or supratherapeutic dosing, or concomitant psychotropic medication — rather than in men taking a single therapeutic-dose tablet with no other risk factors.^[2] Do not confuse this acute, PRN-dosing-pattern risk with the very different, deliberately regimented daily or scheduled PDE5 inhibitor dosing that has separately been studied as a possible preventive strategy for recurrent ischemic priapism (see Special Populations and the Pharmacologic Treatment Options table) — these are two different use patterns of the same drug class with opposite intended effects on priapism risk, and conflating them in patient counselling is a genuine, avoidable error.
• Antipsychotics and antidepressants — alpha-1 adrenergic receptor blockade in the corpora is the proposed shared mechanism. Documented agents include the antidepressant trazodone (historically the classic pharmacologic cause taught in this class), the atypical antipsychotics olanzapine, risperidone, clozapine, and quetiapine, the typical antipsychotic chlorpromazine, and other psychotropic agents including bupropion, fluoxetine, sertraline, and lithium.^[1]
• Alpha-1 adrenergic blockers — doxazosin, prazosin, tamsulosin, and terazosin, used for hypertension and benign prostatic hyperplasia, share the same alpha-1 blockade mechanism and carry the same documented association.^[1] This is a meaningful overlap population: the same older men prescribed an alpha-blocker for BPH symptoms are also the population most likely to develop enteric- or obstruction-related lower urinary tract disease generally, so a new episode of priapism in this group should specifically prompt a medication review.
• Anticoagulants — heparin and warfarin are both documented associated agents.^[1] Anticoagulation is also directly relevant to acute management: a therapeutically anticoagulated patient undergoing corporal aspiration and phenylephrine injection carries a higher bleeding and hematoma risk from the procedure itself, worth flagging explicitly to the treating team, and is a specific consideration in sickle cell disease patients who may also be anticoagulated for an unrelated indication.
• Other antihypertensives (guanethidine, hydralazine, propranolol) and ADHD medications (atomoxetine) are also documented causes, alongside hormone therapy (gonadotropin-releasing hormone agonists, testosterone) and recreational drugs (alcohol, cocaine, marijuana).^[1]

Sickle cell disease and other hematologic disorders

Sickle cell disease (SCD) is the leading non-drug cause of priapism, and by far the most important hematologic cause for a pharmacist to recognize. Priapism occurs in an estimated 23-89% of males with homozygous SCD by age 18, with most experiencing recurrent short, self-limited (stuttering) ischemic episodes lasting under four hours, punctuated less commonly by longer acute ischemic events.^[1] The proposed mechanism is intravascular sickling, aggregation, and hemolysis of red blood cells within the corpora, together with reduced bioavailability of nitric oxide, a key regulator of normal detumescence.^[1] Other hematologic and oncologic conditions documented in association with priapism include thalassemia, hemolytic anemias, polycythemia, thrombotic thrombocytopenic purpura, thrombophilic states (protein C, protein S, or Factor V Leiden deficiency), multiple myeloma, chronic myelogenous or lymphocytic leukemia, and genitourinary solid tumours.^[1] Regardless of the underlying hematologic disorder, the core acute management is identical to any other case of acute ischemic priapism — the disorder changes the concurrent systemic care, not the urgency or sequence of urologic treatment (see Choose Initial Treatment and Special Populations).^[1]

Clinical presentation and the ischemic-versus-non-ischemic differential

Acute ischemic priapism presents with a fully rigid, tender, painful corpora cavernosa; the glans and corpus spongiosum remain soft. Non-ischemic priapism instead produces partial, non-tender tumescence that is often painless, and can persist intermittently for hours to weeks — a chronic, well-tolerated tumescence without full rigidity is a pattern seen with non-ischemic disease and essentially never with true ischemic priapism.^[1] A history of recent pelvic, genital, or perineal trauma — especially a straddle injury — points strongly toward a non-ischemic, fistula-related cause, whereas recent intracavernosal vasoactive drug injection or a personal/family history of sickle cell disease or another hematologic abnormality points toward an ischemic cause.^[1]

^[1]

• Sickle cell disease or another hemoglobinopathy — the leading non-drug cause; a personal or family history should be specifically asked about in every case.^[1]
• Thalassemia, hemolytic anemias, polycythemia, thrombotic thrombocytopenic purpura, protein C/S or Factor V Leiden deficiency, multiple myeloma, chronic leukemias, and genitourinary solid tumours.^[1]
• Intracavernosal injection therapy for erectile dysfunction (alprostadil, papaverine, phentolamine, alone or combined) — the most direct, mechanistically clear drug cause, and higher-dose or combination regimens carry a higher risk than alprostadil alone.^[1]
• PDE5 inhibitor use, particularly at supratherapeutic or recreational doses, combined with ICI therapy, or layered on another risk factor (SCD, spinal cord injury, psychotropic medication).^[2]
• Antipsychotics and antidepressants with alpha-1 adrenergic blocking activity, especially trazodone, and the atypical/typical antipsychotics olanzapine, risperidone, clozapine, quetiapine, and chlorpromazine.^[1]
• Alpha-1 adrenergic blockers (doxazosin, prazosin, tamsulosin, terazosin), anticoagulants (heparin, warfarin), other antihypertensives (guanethidine, hydralazine, propranolol), and ADHD medications (atomoxetine).^[1]
• Recent pelvic, genital, or perineal trauma, especially a straddle injury — the leading risk factor for non-ischemic (fistula-related) priapism specifically.^[1]
• Recreational drug use (alcohol, cocaine, marijuana) and hormone therapy (gonadotropin-releasing hormone agonists, testosterone).^[1]
• A prior episode of ischemic priapism, particularly in SCD or idiopathic disease — the single strongest predictor of recurrent (stuttering) episodes.^[1]

Complications

• Permanent erectile dysfunction — the dominant, genuinely common complication of unrelieved or prolonged acute ischemic priapism, driven directly by the corporal-necrosis timeline described in Recognize the Condition; the risk climbs sharply beyond 24-36 hours and is essentially expected beyond 48-72 hours.^[1]
• Penile shortening and corporal fibrosis, which can complicate future erectile function and, if a penile prosthesis is later needed, make device placement more technically difficult (narrower/shorter cylinders, higher risk of erosion).^[1]
• Distal shunt complications: urethral injury, cavernositis, persistent fistula, infection, and penile skin necrosis.^[1]
• Embolization complications (for non-ischemic priapism): erectile dysfunction, recurrence, and outright failure to correct the fistula.^[1]
• Systemic complications specific to intracavernosal phenylephrine — rare but reported case-level adverse events including hypertensive emergency, myocardial infarction, and intracranial hemorrhage, underscoring why cardiovascular monitoring during ICI phenylephrine administration is a formal guideline requirement, not just good practice.^[1]
• Recurrent (stuttering) priapism itself, which carries a cumulative risk of the above complications with each episode and requires its own long-term prevention discussion (see Special Populations).^[1]

History

• Duration of the current erection and baseline erectile function before this episode.
• Degree of pain — significant pain points toward ischemic disease; a painless, partial erection points toward non-ischemic disease.
• Any previous episode of priapism and how it was treated.
• Use of any drug that might have precipitated the episode — specifically ask about ICI therapy, PDE5 inhibitors, antipsychotics/antidepressants, alpha-blockers, anticoagulants, and recreational drug use.^[1]
• History of pelvic, genital, or perineal trauma, especially a straddle injury.^[1]
• Personal or family history of sickle cell disease or another hematologic abnormality.^[1]
• Personal history of malignancy, particularly genitourinary malignancy.^[1]

Examination

Examine the genitalia, perineum, and abdomen. In priapism, the corpora cavernosa are typically affected while the corpus spongiosum and glans are not; the corpora are often fully rigid and tender in acute ischemic priapism, while men with non-ischemic priapism typically exhibit only partial corporal tumescence.^[1] Abdominal, pelvic, and perineal examination may reveal evidence of trauma or malignancy.^[1]

Corporal blood gas — the primary diagnostic test

A corporal blood gas, obtained by direct aspiration from the corpus cavernosum, is the most useful test for distinguishing acute ischemic priapism from non-ischemic priapism when the diagnosis is not already obvious from history and exam, and should be obtained at the initial presentation of priapism in most cases.^[1] Blood aspirated in acute ischemic priapism is hypoxic and dark red; in non-ischemic priapism it is normally oxygenated and bright red.^[1]

^[1] A corporal blood gas may reasonably be omitted at clinician discretion in certain situations — priapism induced by in-office or at-home ICI therapy, recurrent ischemic priapism (e.g., in SCD) where the diagnosis is already clear from history alone, or any case where the diagnosis is otherwise abundantly clear on history and exam.^[1]

Imaging

Penile duplex Doppler ultrasound is not the primary way to diagnose priapism and should not be used to delay definitive acute treatment, but may be useful when the diagnosis of ischemic versus non-ischemic priapism is genuinely indeterminate on history, exam, and blood gas.^[1] Ischemic priapism findings include bilateral absence of cavernosal arterial flow with low peak systolic velocities (under 50 cm/sec); non-ischemic priapism is instead associated with high peak systolic velocities (over 50 cm/sec), and may show a visible cavernosal artery fistula or pseudoaneurysm.^[1]

Laboratory testing

• Complete blood count — may identify elevated white cell count (malignancy-related priapism, e.g. leukemia) or, in SCD, characteristically low hemoglobin.^[1]
• Reticulocyte count, compared to the patient's own baseline where known — useful in SCD and other hematologic conditions, best interpreted together with the patient's hematologist.^[1]
• Hemoglobin electrophoresis or similar hemoglobinopathy testing — reserved for select scenarios based on clinical suspicion and patient race/ethnicity where SCD has not previously been diagnosed; most men with known SCD have already been diagnosed, so routine testing in every priapism presentation is low-yield.^[1]
• Screening for psychoactive drugs and urine toxicology may be considered, though testing can have a high false-negative rate for synthetic or altered illicit substances, and a thorough medication and social history often provides equivalent information without the need for additional testing.^[1]

• Correctly and rapidly distinguish acute ischemic (emergency) priapism from non-ischemic priapism, since their management is entirely different.
• Relieve corporal ischemia in acute ischemic priapism as fast as safely possible, since the risk of permanent erectile tissue damage grows with every hour of delay.
• In patients with sickle cell disease or another hematologic disorder, deliver standard urologic treatment without delaying it for disease-specific systemic interventions.
• Use intracavernosal phenylephrine safely, with appropriate cardiovascular monitoring, before escalating to surgery.
• Recognize when medical therapy has failed and escalate promptly to surgical shunting rather than persisting indefinitely.
• Counsel every patient honestly about the real, duration-dependent risk of permanent erectile dysfunction.
• Manage non-ischemic priapism as the non-emergency it is, without unnecessary invasive intervention during a reasonable period of observation.
• Identify and, where clinically appropriate, address a drug-induced cause, and provide the specific patient education needed to prevent a repeat episode.
• Discuss realistic, evidence-limited options for preventing recurrent (stuttering) ischemic priapism, including the fertility and sexual-function trade-offs of hormonal prevention strategies.

Why phenylephrine is the preferred intracavernosal agent

Efficacy has also been reported for epinephrine and ethylephrine, but phenylephrine is by far the most frequently used and best-studied agent, associated with a 28% higher rate of detumescence compared to all other reported agents combined, while offering rapid onset, a short duration of action, and relative alpha-1 selectivity that reduces (without eliminating) the potential for adverse cardiovascular effects compared with less selective sympathomimetics.^[1] Its use for this indication is off-label, but it is the recognized agent of choice.^[1]

Dosing, administration, and monitoring

Phenylephrine 100-500 mcg, suspended in 1 mL of normal saline (optimally pre-mixed by pharmacy to minimize the real risk of dosing miscalculation or overdose at the bedside), is injected intracavernosally — never subcutaneously — laterally at the 3 or 9 o'clock position near the base of the penile shaft, using a small needle (e.g., 27 gauge). Doses are given at least 5 minutes apart and treatment may continue for up to about 1 hour; a penile block with local anesthetic should be considered before beginning.^[1] There is no fixed upper limit on the number of injections, but injections should be stopped immediately if blood pressure changes are detected, and if the erection persists despite repeated attempts over roughly an hour, the panel recommends proceeding to definitive surgical shunting rather than continuing medical therapy indefinitely — some clinical scenarios, particularly priapism already exceeding 36 hours, may warrant a more rapid transition to surgery without prolonged attempts at phenylephrine and aspiration/irrigation.^[1]

Blood pressure and heart rate monitoring is required in every patient receiving intracavernosal phenylephrine for acute ischemic priapism, given the alpha-adrenergic effect and the real, if uncommon, potential for systemic absorption and adverse cardiovascular effects, including case reports of myocardial infarction, hypertensive emergency, and intracranial hemorrhage associated with intracavernosal sympathomimetic use.^[1] Monitoring is especially prudent in patients with a history of cardiovascular disease, hypertension, prior stroke, or current use of monoamine oxidase inhibitors (MAOIs) — while there are no reports of toxicity specifically from intracavernosal phenylephrine in men on an MAOI, the interaction risk with oral phenylephrine is well established, so gradual, low-starting-dose escalation is a reasonable precaution when parenteral phenylephrine is genuinely necessary in this population.^[1]

Corporal aspiration and irrigation — technique

Corporal aspiration refers to the intracavernosal placement of a needle followed by withdrawal of trapped corporal blood; irrigation refers to subsequent instillation of fluid (typically saline) into the corpora. The two procedures are usually combined, and combined with phenylephrine injection, to remove clotted, deoxygenated blood and help restore normal arterial inflow and smooth-muscle/endothelial function.^[1] A representative protocol: place a 16-18 gauge butterfly needle at the 3 or 9 o'clock position near the base of the penis, connect it to a 30-60 mL Luer-lock syringe, and alternate aspirating clotted blood with instilling saline until some degree of detumescence is achieved; then instill phenylephrine and allow 3-5 minutes to pass before repeating the cycle as needed.^[1]

If temporary detumescence is achieved with aspiration but blood rapidly refills the corpora despite repeated phenylephrine instillation, a firm penile wrap applied at the time of aspiration may help maintain detumescence.^[1]

Surgical shunt procedures for medically refractory ischemic priapism

When intracavernosal phenylephrine and aspiration/irrigation fail to achieve lasting detumescence, a distal corporoglanular shunt — with or without corporal tunneling — is the recommended next step, performed before considering a proximal shunt.^[1] No single distal technique (Winter's, Ebbehoj, Al-Ghorab, or T-shunt) has been shown superior to the others in comparative studies, and the choice is largely one of surgeon experience and preference.^[1] Corporal tunneling ("snake maneuver") — passing a dilator proximally through the distal shunt opening to evacuate clotted blood from the proximal corpora — should be considered if the erection persists after a distal shunt alone, though the available data suggest tunneling may come at some additional cost to long-term erectile function preservation compared with shunting alone.^[1] If a distal shunt with tunneling still fails, a proximal shunt (Quackels: cavernosum-to-spongiosum; Grayhack: cavernosum-to-saphenous vein; or Barry: cavernosum-to-deep dorsal vein) may be considered, though the panel is explicit that there is inadequate evidence to quantify its benefit, and in practice proximal shunting has largely been replaced by distal shunting with tunneling — it is not a mandatory next step after failed distal shunting, but one of several options.^[1]

Before any repeat surgical intervention for a persistent erection following a shunt procedure, obtain a corporal blood gas or colour duplex ultrasound to confirm true persistent ischemia (versus reactive post-operative edema or hyperemia mimicking unresolved priapism, and versus a shunt that has already restored oxygenated arterial inflow) — this avoids an unnecessary second surgery based on exam findings alone.^[1]

Penile prosthesis

Placement of a penile prosthesis may be considered in a patient with untreated acute ischemic priapism greater than 36 hours, or in those refractory to shunting with or without tunneling — reflecting the reality that beyond this duration, meaningful spontaneous erectile function recovery is unlikely regardless of which detumescence procedure is ultimately used.^[1] The choice between early (generally within about two weeks) versus delayed placement involves real trade-offs that should be discussed explicitly with the patient: pooled data suggest delayed placement is associated with a significantly higher rate of penile shortening, higher infection rates, and more revision surgery, while early placement has its own risks, including operating on tissue where the true extent of necrosis is not yet fully demarcated.^[1] This decision should be reached through shared decision-making, factoring in the patient's baseline erectile function, overall condition, and the treating urologist's experience with prosthesis placement in this setting.^[1]

Non-ischemic priapism — observation first

Diagnosed non-ischemic priapism is not a medical emergency, and the recommended first step is an initial period of observation, since many arterial-sinusoidal fistulae close spontaneously; in the absence of strong evidence defining an optimal duration, roughly four weeks is a reasonable default period before re-evaluating with penile duplex ultrasound.^[1] If the fistula persists after observation and the patient — now aware of the risks and benefits — wishes to proceed with treatment, percutaneous selective embolization performed by an experienced interventional radiologist is first-line therapy; if the first embolization attempt fails, a second attempt is generally preferred over surgical ligation, favouring more durable (non-resorbable) embolic material on the retry given how few urologists today have real experience with surgical ligation and the generally poor supporting data for it.^[1]

Sickle cell disease

Patients with SCD and acute priapism — including pre-pubertal boys — should initially be managed with a focus on urologic relief of the erection exactly as outlined for any other patient: standard treatment should never be delayed for disease-specific systemic interventions.^[1] Concurrent, disease-specific SCD care should proceed alongside urologic treatment, not instead of it or before it, and should specifically address:^[1]

• Hydration with IV fluid only if the patient is NPO (at maintenance rate) or clinically dehydrated (replacing the deficit plus maintenance); hyperhydration is not indicated and may actually predispose to acute chest syndrome.^[1]
• Supplemental oxygen only if the patient is hypoxic — not routinely.^[1]
• Pain management with oral or parenteral opioids as for any other acute painful SCD event, recognizing that some patients may have developed tolerance to analgesia from prior painful episodes.^[1]
• Hematologic status assessment — CBC and reticulocyte count compared to the patient's own baseline, ideally in consultation with their hematologist. Transfusion is not indicated if hemoglobin is near the patient's usual value, and over-transfusion carries its own risk of acute neurologic events.^[1]
• Screening for other concurrent acute SCD events (stroke, acute chest syndrome, biliary colic, renal insufficiency), which — while not associated with a higher frequency of priapism specifically — can present at the same time.^[1]
• Never using ice packs or other cold compresses, which can worsen a painful SCD event by precipitating intravascular sickling.^[1]

Exchange transfusion should not be used as the primary treatment for acute ischemic priapism in SCD — delaying known effective intracavernosal phenylephrine and aspiration therapy in order to plan and perform an acute exchange transfusion is not warranted, particularly since antigen-matched red cell products typically take six or more hours to prepare, time during which the priapism episode itself continues to cause ischemic damage.^[1] Exchange transfusion may still be considered for a genuinely prolonged acute episode that has not responded to standard intracavernosal therapy; if operative shunting becomes necessary, a simple transfusion of packed red blood cells to raise hemoglobin to 9-10 g/dL prior to general anesthesia is a reasonable, distinct step.^[1] For long-term prevention, ongoing chronic (monthly) exchange or simple manual transfusion programs, and hydroxyurea, both appear associated with a reduced frequency of subsequent acute and stuttering priapism episodes, though the evidence for hydroxyurea specifically preventing priapism (as opposed to other SCD complications) is not conclusively proven; the decision to pursue a chronic transfusion program should be made jointly between the patient and their primary hematologist.^[1]

Patients receiving intracavernosal injection therapy for erectile dysfunction

Every patient who receives ICI teaching, or who has a pharmacologically induced erection produced in-office, must be explicitly instructed to return to the office or the emergency department if the erection lasts more than four hours.^[1] A persistent erection of four hours or less following ICI therapy is treated as its own distinct entity, not automatically as priapism: intracavernosal phenylephrine is the appropriate initial treatment option if the patient wants resolution or if simple conservative measures (ice, exercise, ejaculation) have failed, but these conservative measures should never be used in place of, or to prolong, effective treatment once a fully rigid erection has genuinely passed four hours.^[1] Clinicians who lack the training, facilities, or hospital privileges to fully manage ischemic priapism, including surgical management if required, should not be administering in-office intracavernosal erectogenic therapies in the first place.^[1]

Pediatric and refractory priapism

Priapism in prepubertal boys is most often related to sickle cell disease, but can also occur idiopathically or following trauma, and should be managed with the same urgency as in adults. A Canadian case report illustrates an important teaching point for genuinely refractory pediatric priapism: an 8-year-old boy whose priapism persisted despite aspiration, intracavernosal adrenergic injection, and then sequential distal shunt procedures (Winter's, followed by Al-Ghorab) was ultimately found on angiography to have an underlying arteriovenous fistula, resolved only with targeted embolization.^[3] The lesson generalizes beyond pediatrics: a patient who is genuinely refractory to repeated standard interventions warrants a specific search for an unusual underlying vascular anomaly rather than simply repeating the same shunt procedure a third or fourth time.^[3]

Recurrent (stuttering) ischemic priapism

Patients with recurrent ischemic priapism should be told plainly that the optimal strategy to prevent subsequent episodes is not known — no single preventive approach has strong supporting evidence.^[1] Reported options for idiopathic stuttering priapism include oral baclofen, dutasteride or finasteride, regimented (scheduled, not as-needed) PDE5 inhibitor dosing, ketoconazole paired with a steroid-sparing agent, pseudoephedrine, and aspirin; for SCD-associated stuttering priapism, the same general options apply alongside hydroxyurea and a scheduled exchange transfusion program.^[1] Hormonal regulator therapy (ketoconazole, antiandrogens, GnRH-axis manipulation) carries a real, clinically important trade-off: it may impair fertility and sexual function, a discussion that should happen explicitly and in advance, particularly with younger men who have not completed childbearing.^[1] Home self-injection of phenylephrine on an as-needed basis is a reasonable option for some appropriately trained patients experiencing a recurrent episode, but this is a treatment for individual episodes, not itself a preventive strategy.^[1]

• Reassess detumescence continuously during intracavernosal phenylephrine and aspiration/irrigation, with blood pressure and heart rate monitoring throughout the encounter.^[1]
• After successful acute treatment, counsel every patient honestly about the real, duration-dependent risk of erectile dysfunction, and arrange urology follow-up to assess erectile function over time — this discussion should happen even after apparently successful detumescence, since function loss can still emerge over the following weeks.^[1]
• After a distal shunt procedure with a persistent erection, obtain a corporal blood gas or colour duplex ultrasound before assuming treatment has failed and proceeding to further surgery.^[1]
• Patients on ketoconazole for recurrent-priapism prevention need baseline and periodic liver function testing given its real hepatotoxicity risk.^[1]
• Patients with SCD should have ongoing follow-up with both urology and their hematologist, including discussion of a chronic transfusion program or hydroxyurea if episodes are frequent.^[1]
• Any patient started on ICI therapy for erectile dysfunction after a prior priapism episode should have their dose and regimen specifically reviewed with the prescribing clinician before resuming therapy.
• For non-ischemic priapism managed with observation, re-evaluate with penile duplex ultrasound at around 4 weeks to determine whether the fistula has closed spontaneously.^[1]

1. No detumescence after intracavernosal phenylephrine and corporal aspiration ± irrigation for up to about 1 hour: proceed to distal corporoglanular shunt (Winter's, Ebbehoj, Al-Ghorab, or T-shunt), with or without corporal tunneling — do not continue medical therapy indefinitely, and consider a more rapid transition to surgery if the episode has already exceeded 36 hours.^[1]
2. Persistent erection after a distal shunt: obtain a corporal blood gas or colour duplex ultrasound first, to confirm true persistent ischemia rather than reactive post-operative edema or hyperemia, before proceeding to any further intervention.^[1]
3. Confirmed persistent ischemia after a distal shunt with tunneling: consider a proximal shunt (Quackels, Grayhack, or Barry procedure) or early placement of a penile prosthesis, particularly if the episode now exceeds 36 hours or the patient is refractory to shunting — this decision is individualized and should involve shared decision-making about the trade-offs of early versus delayed prosthesis placement.^[1]
4. Genuinely refractory priapism despite repeated standard shunting, especially in a pediatric patient: consider angiography to look for an underlying arteriovenous fistula rather than repeating the same shunt procedure again.^[3]
5. Non-ischemic priapism persisting after an adequate period of observation, with the patient wishing treatment: percutaneous selective embolization by an experienced interventional radiologist.^[1]
6. Non-ischemic priapism recurring after a first embolization attempt: offer a second embolization attempt, generally favouring non-resorbable embolic material on retry, in preference to surgical ligation.^[1]
7. Recurrent (stuttering) ischemic priapism despite appropriate acute management of each episode: refer for a structured discussion of preventive options (regimented PDE5 inhibitor dosing, baclofen, dutasteride/finasteride, ketoconazole, or — in SCD — hydroxyurea/scheduled exchange transfusion), with explicit counselling on the fertility and sexual-function trade-offs of hormonal options.^[1]

• Trying "conservative" self-help measures — observation, oral medication, cold compresses, exercise — as an initial strategy for acute ischemic priapism instead of immediate intracavernosal therapy; these measures are unlikely to work and should never delay definitive treatment.^[1]
• Using ice packs, cold compresses, or cold saline irrigation in a patient with sickle cell disease — this can precipitate intravascular sickling and worsen the acute event.^[1]
• Waiting for hydration, oxygen, or exchange transfusion to be arranged in an SCD patient before starting standard intracavernosal phenylephrine and aspiration therapy — the urologic treatment should proceed concurrently, not after.^[1]
• Administering intracavernosal phenylephrine without blood pressure and heart rate monitoring, or failing to use extra caution (low starting dose, gradual escalation) in a patient on an MAOI or with known cardiovascular disease.^[1]
• Treating non-ischemic priapism as an emergency and rushing to embolization without first offering a reasonable period of observation, given how often the underlying fistula closes spontaneously.^[1]
• Confusing as-needed or supratherapeutic PDE5 inhibitor use (a documented cause of acute priapism) with deliberately regimented, scheduled PDE5 inhibitor dosing (an investigational strategy for preventing recurrent stuttering priapism) — these are opposite use patterns of the same drug class and should never be conflated in patient counselling.
• Recommending oral pseudoephedrine or terbutaline as definitive treatment for a true priapism episode — neither has been shown reliably effective, and relying on them risks delaying real treatment past the point where erectile tissue damage becomes irreversible.^[1]
• Not explicitly counselling every patient starting intracavernosal injection therapy for erectile dysfunction that any erection lasting more than four hours requires immediate return to care.^[1]
• Assuming a persistent erection after a shunt procedure automatically means the shunt failed, without first checking a corporal blood gas or duplex ultrasound to rule out reactive edema or hyperemia.^[1]
• Starting hormonal-regulator therapy for recurrent priapism prevention without first discussing its potential impact on fertility and sexual function, particularly in a younger man.^[1]
• Repeating the same shunt procedure a third or fourth time in a genuinely refractory case, rather than considering an underlying arteriovenous fistula that needs angiography and embolization.^[3]

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Acute Ischemic Priapism — First-Line Intracavernosal Therapy

Confirm acute ischemic priapism first (see Assessment & Diagnosis and the Clinical Decision Algorithm). Continuous blood pressure and heart rate monitoring is required throughout administration.

Drug-Induced Priapism — Documented Causative Agents by Class

Pharmacist-relevant etiology screen: ask specifically about each of these classes when a cause is not otherwise obvious. A documented association does not always mean the agent must be stopped — that decision belongs to the prescriber, balanced against the indication being treated — but it should always prompt a medication review and be flagged clearly in the chart.

Preventive/Chronic Therapy for Recurrent (Stuttering) Ischemic Priapism

No strategy has strong evidence of benefit — every option below is discussed as a shared-decision conversation, not a guideline-mandated first choice. Hormonal-regulator options specifically require an explicit fertility/sexual-function discussion before starting.